Cochrane Evidence Synthesis and Methods ►

Conversion of calcineurin inhibitor treatment to target of rapamycin inhibitor treatment versus continuation of calcineurin inhibitor treatment for liver transplant recipients

This review aims to assess the benefits and harms of conversion of calcineurin inhibitor treatment to mTor inhibitor treatment compared with continuation of calcineurin inhibitor treatment for liver transplant recipients.

This is a protocol.

Health topics:

Gastroenterology & hepatology > Liver disorders > Transplantation

Published:

8 December 2010

Authors:

Penninga L, Wettergren A, Chan A-W, Steinbrüchel DA, Gluud C

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Penninga L, Wettergren A, Chan A-W, Steinbrüchel DA, Gluud C. Conversion of calcineurin inhibitor treatment to target of rapamycin inhibitor treatment versus continuation of calcineurin inhibitor treatment for liver transplant recipients. Cochrane Database of Systematic Reviews 2010, Issue 11. Art. No.: CD008853. DOI: 10.1002/14651858.CD008853